摘要
米哚妥林(midostaurin,Rydap~)是瑞士诺华制药公司开发的一种口服多激酶受体抑制药。2017年5月被美国食品药品监督管理局批准上市,主要用于治疗携带FMS样酪氨酸激酶-3(FMS-like tyrosinekinase 3,FLT3)突变的急性髓系白血病(AML)。本文对米哚妥林的药效学、药动学特性、临床研究以及安全性等作一介绍,为其临床应用提供参考。
Midostaurin is an orally administered inhibitor of multiple tyrosine kinase receptors developed by Novartis Pharmaceuticals. In May 2017,it was approved in the USA for the treatment of adult patients with newly diagnosed FMS-like tyrosine kinase 3（ FLT3） mutation-positive acute myeloid leukaemia（ AML）. Its pharmacokinetics,pharmacodynamics,clinical trials,adverse effects and drug interactions were introduced in the paper.
出处
《中国药师》
CAS
2018年第3期490-492,共3页
China Pharmacist
